# Effect of Secukinumab on Cardiorenal Outcomes in Patients With Cardiorenal Metabolic Syndrome and Atherosclerotic Cardiovascular Disease

Study · id `cardio:ct-nct07704190` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07704190](<https://clinicaltrials.gov/study/NCT07704190>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07704190

Browse, organ or system: Heart; Blood vessels; Brain; Kidneys; Metabolism  
Browse, condition area: High blood pressure; Coronary and vascular disease; Stroke; Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 100 participants.

## Technical summary

Registry record NCT07704190. Randomized; no masking; primary purpose treatment. Start 2026-07-15 (anticipated); primary completion 2028-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT07704190, source copy `cardio:ctgov-nct07704190-2026-07-15`, retrieved 2026-10-26)
- Planned start: 2026-07-15 (anticipated) (ClinicalTrials.gov record NCT07704190, source copy `cardio:ctgov-nct07704190-2026-07-15`, retrieved 2026-10-26)
- Primary completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT07704190, source copy `cardio:ctgov-nct07704190-2026-07-15`, retrieved 2026-10-26)
- Completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT07704190, source copy `cardio:ctgov-nct07704190-2026-07-15`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07704190-2026-07-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Secukinumab on Cardiorenal Outcomes in Patients With Cardiorenal Metabolic Syndrome and Atherosclerotic Cardiovascular Disease
- Condition: Cardiorenal Metabolic Syndrome
- Condition: Atherosclerotic Cardiovascular Disease
- Condition: Chronic Kidney Disease
- Condition: Coronary Artery Disease
- Condition: Hypertension
- Condition: Type 2 Diabetes Mellitus
- Condition: Peripheral Arterial Disease
- Condition: Carotid Artery Stenosis
- Intervention (Biological): Secukinumab (75 mg)
- Intervention (Other): Standard Medical Therapy
- Lead sponsor: Peking University Third Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Carotid artery stenosis (`cardio:carotid-stenosis`)
- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Peking University Third Hospital (`cardio:org-peking-university-third-hospital`)

## Provenance

Content hash: bc400021cf3d1bfce11cfdf665a75348e27faad289850f447cb49cba17a0c324
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
